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Abstract
This review aims to outline the most up-to-date know-
ledge of pancreatic adenocarcinoma risk, diagnostics, 
treatment and outcomes, while identifying gaps that 
aim to stimulate further research in this understudied 
malignancy. Pancreatic adenocarcinoma is a lethal 
condition with a rising incidence, predicted to become 
the second leading cause of cancer death in some 
regions. It often presents at an advanced stage, which 
contributes to poor five-year survival rates of 2%-9%, 
ranking firmly last amongst all cancer sites in terms of 
prognostic outcomes for patients. Better understanding 
of the risk factors and symptoms associated with this 
disease is essential to inform both health professionals 
and the general population of potential preventive 
and/or early detection measures. The identification of 
high-risk patients who could benefit from screening 
to detect pre-malignant conditions such as pancreatic 
intraepithelial neoplasia, intraductal papillary mucinous 
neoplasms and mucinous cystic neoplasms is urgently 
required, however an acceptable screening test has 
yet to be identified. The management of pancreatic 
adenocarcinoma is evolving, with the introduction 
of new surgical techniques and medical therapies 
such as laparoscopic techniques and neo-adjuvant 
chemoradiotherapy, however this has only led to modest 
improvements in outcomes. The identification of novel 
biomarkers is desirable to move towards a precision 
medicine era, where pancreatic cancer therapy can be 
tailored to the individual patient, while unnecessary 
treatments that have negative consequences on quality 
of life could be prevented for others. Research efforts 
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must also focus on the development of new agents 
and delivery systems. Overall, considerable progress 
is required to reduce the burden associated with 
pancreatic cancer. Recent, renewed efforts to fund large 
consortia and research into pancreatic adenocarcinoma 
are welcomed, but further streams will be necessary to 
facilitate the momentum needed to bring breakthroughs 
seen for other cancer sites. 
Key words: Pancreatic cancer; Pancreatic adenocarci-
noma; Pancreatic cancer risk factors; Pancreatic cancer 
treatment
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The incidence of pancreatic adenocarcinoma 
is rising in the developed world and modifiable life-
style factors such as alcohol and obesity may play an 
important role in this. The five-year survival from this 
disease is as low as 2% in some countries, despite 
improvement in surgical technique, chemotherapy 
regimens and the introduction of neo-adjuvant 
chemoradiotherapy. The poor outcomes are largely due 
to the late presentation of the disease and therefore the 
detection of early tumours or premalignant conditions 
is essential for treatment to be initiated early. The 
optimum screening test is however yet to be identified. 
Given the poor outcomes and current gaps in knowledge 
surrounding this malignant process, further research is 
essential to understand this disease better, enable early 
diagnosis and improve survival. 
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, 
McCain RS. Pancreatic cancer: A review of clinical diagnosis, 
epidemiology, treatment and outcomes. World J Gastroenterol 
2018; 24(43): 4846-4861  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i43/4846.htm  DOI: http://dx.doi.
org/10.3748/wjg.v24.i43.4846
INTRODUCTION
Pancreatic adenocarcinoma is a lethal condition with 
poor outcomes and an increasing incidence. This review 
presents the most up to date knowledge on the incidence, 
outcomes, risk factors, pathogenesis, diagnostics, 
investigated biomarkers and treatments available to 
pancreatic adenocarcinoma patients. This review focuses 
on pancreatic adenocarcinoma where possible, however in 
some places where the general term “pancreatic cancer” 
is used, it should be assumed that the majority of cases 
are pancreatic ductal adenocarcinomas.
INCIDENCE
Pancreatic cancer is ranked as the 14th most common 
cancer and the 7th highest cause of cancer mortality 
in the world. Globocan estimates revealed that there 
will be 458918 diagnoses and 432242 deaths from 
pancreatic cancer globally in 2018[1]. The incidence rates 
vary significantly between countries, as demonstrated 
in Figure 1. The highest age-standardised incidence 
is seen in Europe and North America, and the lowest 
in Africa and South Central Asia[2]. There is a general 
trend of higher incidence rates in developed countries 
compared to developing countries and this is supported 
by Wong et al[3] who demonstrated that in higher human 
development index countries there are higher incidences 
of pancreatic cancer in both males and females. 
A major concern is that the incidence of pancreatic 
cancer is increasing in the Western world. One example 
of this is a study performed by Saad et al[4] using data 
from the United States Surveillance, Epidemiology, and 
End Results Program (SEER) which found that, between 
1973 and 2014, the age-standardised incidence rates 
of pancreatic cancer have increased by 1.03% per year. 
This translates to pancreatic cancer being predicted to 
rise from being the 4th to the 2nd most common cause of 
cancer-related death in the United States by 2030[5,6]. 
The large disparities in pancreatic cancer incidence 
between countries also suggest that environmental 
factors play a significant role as risk factors for the 
disease, and these are discussed below. 
RISK FACTORS
Due to the relatively low incidence and poor survival 
of pancreatic cancer, the risk factors associated with 
the development of this disease have historically been 
investigated using case-control studies. Unfortunately, 
these study designs do have weaknesses including 
selection bias and recall bias. Consortia pooling data from 
multiple cohort studies are needed to overcome sample 
size issues in prospective studies, and these have been 
published more frequently in recent years. The best 
available evidence is presented below in the sections 
divided into non-modifiable and modifiable risk factors 
and the evidence behind the latter is summarised in 
Table 1[7-26]. There is also some preliminary evidence that 
some of these lifestyle factors can influence survival, but 
this is an area that requires further research[7,8]. 
NON-MODIFIABLE RISK FACTORS
Age
Pancreatic cancer is typically a disease of the elderly. It 
is extremely rare for patients to be diagnosed before 
the age of 30, and 90% of newly diagnosed patients are 
aged over 55 years of age, with the majority in their 7th 
and 8th decade of life[9,10]. The age at which the incidence 
peaks varies between countries. In India, for example, 
there is a peak in incidence in patients in their sixth 
decade of life whereas the in the United States this is the 
seventh decade of life[9].
Sex
The worldwide incidence of pancreatic cancer is higher 
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in males than females (Age-standardised rate 5.5 in 
males compared to 4.0 in females)[1]. This disparity 
appears to be greater in higher development index 
countries[7]. Despite the sex difference, a systematic 
review of 15 studies concluded that reproductive factors 
were not associated with pancreatic cancer in women[11]. 
These findings point towards differing exposures 
in environmental or genetic factors as alternative 
explanations for the male predominance. 
Ethnicity
Within the United States, a 50%-90% increased risk 
of pancreatic cancer in African-Americans compared to 
Caucasians has been reported, while incidence rates 
are lowest in Pacific Islanders and Asian-Americans[9]. 
The higher incidence rates within the African-American 
population is proposed to be linked to a greater exposure 
to other risk factors for pancreatic cancer, such as 
cigarette smoking, alcohol consumption, elevated body 
mass index and higher incidence of diabetes[12], but 
there is also evidence for underlying genetic or gene 
environment interactions to explain at least some of 
the observed differences in incidence between ethnic 
groups[13,14]. 
Blood group 
The risk of developing pancreatic adenocarcinoma has 
been shown to be associated with different ABO blood 
groups in several large epidemiological studies. Wolpin 
et al[15] combined data from the renowned United States 
Nurse Health Study and Health Professionals Follow-up 
Study, and found that compared to blood patients with 
blood group O, patients with blood group A (HR: 1.32, 
95%CI: 1.02-1.72), AB (HR: 1.51, 95%CI: 1.02-2.23), 
or B (HR: 1.72, 95%CI: 1.25-2.38) were at a significantly 
higher risk of developing pancreatic adenocarcinoma. 
Results from the Pancreatic Cancer Cohort Consortium 
which combined data from 12 prospective cohort 
studies was in agreement with these findings[16]. The 
proposed mechanisms behind this include alterations in 
glycosyltransferase specificity and the host inflammatory 
state across the different ABO blood groups[15]
Gut Microbiota
Multiple studies have been performed examining the 
role of gut microbiota in pancreatic cancer. A systematic 
review by Memba et al[17] demonstrated that lower levels 
of Neisseria elongate and Streptococcus mitis, and higher 
levels of Porphyromonas gingivalis and Granulicatella 
adiacens are associated with an increased risk of 
pancreatic cancer. However, further studies are needed 
to validate these findings and also to establish if targeted 
treatment is a therapeutic possibility. 
Family history and genetic susceptibility
Pancreatic cancer is considered to be familial if two 
or more first degree relatives have previously been 
diagnosed with the disease and accounts for 5%-10% 
of new cases[27]. Patients with familial risk factors have 
a nine times higher risk of developing pancreatic cancer 
than those with no family history, and this increases to a 
thirty-two times greater risk if three or more first degree 
relatives have been previously diagnosed[28]. A meta-
analysis of nine studies has also reported that individuals 
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Figure 1  Diagram of incidence of pancreatic cancer in both sexes throughout the world Adapted from Globocan[1] 2018.
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strongly positive association. The Panc4 study combined 
data from 12 case-control studies of which there were 
6507 cancer cases and 12890 controls. The results 
demonstrated a dose responsive significantly increased 
risk of pancreatic cancer in ever smokers[18]. A meta-
analysis of 82 published studies found that there is 
a 74% increased risk of pancreatic cancer in current 
(OR: 1.74, 95%CI: 1.61-1.87) and a 20% increased 
risk in former smokers (OR: 1.20, 95%CI: 1.11-1.29) 
compared to never smokers[19]. This study also found 
that following smoking cessation the risk remains for at 
least 10 years[19] while others have shown it may take 
up to 20 years following smoking cessation for the risk 
to return to baseline[9]. The Pancreatic Cancer Cohort 
Consortium has reported similar findings, and also found 
the risk increased with both duration of smoking (> 50 
years OR: 2.13, 95%CI: 1.25-3.62) and number of 
cigarettes smoked (> 30 cigarettes/d, OR: 1.75, 95%CI: 
1.27-2.42)[20]. 
A novel area for future research remains unan-
swered in relation to e-cigarettes and pancreas health. 
E-cigarettes deliver heated nicotine, but fewer chemicals 
than tobacco smoking, and have generally been 
promoted as safer (but not necessarily safe) alternatives 
to traditional cigarettes[35]. New studies are required to 
determine the risk/benefit balance of e-cigarettes as an 
exposure with unknown carcinogenic potential, or as a 
helpful smoking cessation tool contributing to pancreatic 
cancer prevention[35].
Alcohol
Multiple studies have investigated the impact of 
alcohol consumption on the development of pancreatic 
cancer but thus far results have been mixed[9,21,22]. A 
pooled analysis of 14 cohort studies with 2187 cases 
of pancreatic cancer found an increased risk when 
patients consumed > 30 g of alcohol per day (RR: 1.22, 
with a family history of pancreatic cancer were only one 
first degree relative has been diagnosed with pancreatic 
cancer, still have an 80% increased risk of developing 
pancreatic adenocarcinoma (RR: 1.8, 95%CI: 1.48-2.12) 
compared with individuals with no reported family 
history[29].
This points towards a strong genetic susceptibility for 
pancreatic cancer in a subgroup of affected patients. In 
familial pancreatic cancer, the risk rises exponentially with 
the number of first degree relatives affected and BRCA2 
and PALB are the most commonly implicated mutations 
in this cohort[2,9]. Specific syndromes are also associated 
with an increased risk of pancreatic cancer compared to 
the general population. These are summarised in Table 
2[30,31].
Diabetes
Diabetes is a well-established risk factor for pancreatic 
cancer. Stevens et al[32] performed a meta-analysis which 
demonstrated that the risk of pancreatic cancer was 
twice that in patients with type one diabetes compared 
to those without this condition (RR: 2.00, 95%CI: 
1.37-3.01). Another comprehensive meta-analysis of 
36 studies also demonstrated a similar magnitude of 
increased risk of pancreatic cancer in patients with type-2 
diabetes (OR: 1.82 95%CI: 1.66-1.89)[33]. However, it 
must be noted that although diabetes is a risk factor, 
pancreatic cancer can also manifest itself as new onset of 
diabetes. This has led to interest in HbA1c as a potential 
biomarker of early detection in pancreatic cancer[34].
MODIFIABLE RISK FACTORS
Smoking
Cigarette smoking is considered the most important 
modifiable risk factor in pancreatic cancer with multiple 
individual and combined studies demonstrating a 
Factor Direction of 
association
Strength of association Type of studies 
conducted
Related notable findings Ref.
Smoking Positive Strong association; 74% increased risk 
in current smokers; 20% increased risk 
in former smokers
Case-control, cohort, 
nested case-control 
studies
Dose responsive; risk remains 10-20 
yr following smoking cessation
[18-20]
Alcohol Mixed between 
no association and 
positive
Various; 15%-43% increased risk in 
meta-analysis
Meta-analysis of cohort 
studies
Dose responsive; sex dependent; 
Increased risk in spirit drinkers; 
link with chronic pancreatitis which 
is a risk factor for pancreatic cancer
[9,21-24]
Obesity Positive 10% increased risk for every 5 BMI 
units
Cohort studies Link with Type 2 diabetes which 
is associated with increased risk of 
pancreatic cancer
[25]
Dietary factors Variable Non-significant positive association for 
red meat; 17% increased risk associated 
with 50 g/d of processed meat 
consumption compared to 20 g/d
Cohort studies Overall consensus cannot be made 
and further research is required
[25]
Helicobacter pylori Positive 45% increased risk Meta-analysis of case-
control studies
Significant publication bias and 
small numbers included therefore 
further studies are required
[26]
Table 1  Summary of modifiable risk factors associated with pancreatic cancer
McGuigan A et al . A review of pancreatic cancer
BMI: Body mass index.
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95%CI: 1.03-1.45)[23]. The most recent meta-analysis 
found that low and moderate alcohol consumption was 
not associated with pancreatic cancer risk, however, in 
those with a high alcohol consumption there was a 15% 
increased risk of pancreatic cancer (RR: 1.15, 95%CI: 
1.06-1.25; P = 0.001)[24]. This increased risk was 
strongest in heavy male drinkers and heavy drinkers of 
spirits[24].
Excessive alcohol consumption is also the main cause 
of chronic pancreatitis, which is a known risk factor for 
pancreatic cancer and therefore alcohol in this setting is a 
risk factor for pancreatic cancer[36]. 
Chronic pancreatitis 
Chronic pancreatitis is a progressive inflammatory 
condition of the pancreas leading to fibrosis and loss 
of acinar and islet cells. Significant variety exists in 
the reported incidence of this disease, ranging from 
2-14/100000 of the United States population[37]. Approxi-
mately 5% of these patients will develop pancreatic 
cancer a during their lifetime[38]. Pooled results from 
seven studies investigating chronic pancreatitis and found 
significantly 13-fold higher risk of pancreatic cancer (RR: 
13.3, 95%CI: 6.1-28.9) in these patients, compared 
with the general population or controls[38]. The relatively 
low incidence and greater risk infers that of chronic 
pancreatitis patients could be a potential target group 
for pancreas cancer screening, if an effective test can be 
found and long latency period accounted for. 
Obesity
The worldwide prevalence of obesity is increasing with 
an estimated 1.97 billion adults and 338 million children 
and adolescents categorised worldwide as overweight or 
obese in 2016[25]. The World Cancer Research Fund in the 
pancreatic cancer report from 2012 identified 23 studies 
which assessed for an association between a raised 
body mass index (BMI) and pancreatic cancer. Nineteen 
of these individual studies reported an increased risk 
of pancreatic cancer in obese patients and in the meta-
analysis performed of these studies there was a 10% 
increased risk of pancreatic cancer for every 5 BMI units 
(RR: 1.10, 95%CI: 1.07-1.14) with no difference in 
outcomes between males and females[25].
Given the strength of the evidence linking obesity to 
pancreatic cancer, it is likely that the rising incidence of 
obesity is a major factor for the increasing incidence of 
pancreatic cancer in the developed world. There have 
been large public health campaigns around some of 
the other major lifestyle with a subsequent decrease 
in alcohol consumption and cigarette smoking. Similar 
campaigns need to focus on educating the public on the 
health risks associated with obesity. 
Dietary factors
Table 3 provides a concise review of the impacts of diet 
and nutrition on the risk of pancreatic cancer according 
to the World Cancer Research Fund global report. There 
is limited suggestive evidence that red and processed 
meat consumption are association with pancreas cancer 
development. This is biologically plausible given that 
excessive consumption of red and processed meat has 
been shown to potentially cause DNA damage and 
the formation of carcinogens such as N-nitroso com-
pounds[25]. Other dietary factors with limited suggestive 
evidence in pancreatic cancer aetiology include foods 
and beverages containing fructose, or foods containing 
saturated fatty acids; while no conclusions could be made 
with regards to other dietary exposures. This reflects the 
difficulties in nutritional epidemiology and appropriate 
study designs for investigating pancreatic cancer risk. 
Infection
The relationship between several infections and pancreatic 
cancer has also been investigated, with increased risks 
observed in patients with Helicobacter pylori (H-pylori)[26] 
or hepatitis C infections[39]. Further studies are necessary 
to strengthen these findings[26]. The potential association 
for H-pylori raises interesting speculation about H-pylori 
eradication (intended to reduce gastric cancer risk) having 
potentially negative consequences for increasing pancreas 
cancer incidence, as has been noted for oesophageal 
adenocarcinoma trends[40]. 
Outcome
The worldwide 5-year survival rate for pancreatic cancer 
patients is approximately 6%, but this ranges from 2% 
to 9% in published literature[2,41,42]. Factors that impact on 
survival include age, sex, quality of healthcare available, 
presence of co-morbidities and lifestyle habits and some 
of these account for the difference in survival rates 
between countries. However, the main factor influencing 
Gene Syndrome Increase relative risk vs  general population
Chen et al [30] Del Chiaro et al [31]
BRCA2 Hereditary breast and ovarian cancer 2.2-5.9
BRCA1 1.6-4.7
STK11 Peutz-Jeghers syndrome   76.2-139.0 132.0
PRSS1 Hereditary pancreatitis 53-87 50-70
CDKN2A Familial atypical multiple mole melanoma 14.8-80.0 34-39
MMR Hereditary nonpolyposis colorectal cancer   0.0-10.7     4.7
Table 2  Range of increased relative risk of pancreatic cancer associated with specific syndromes as summarised by Chen et al [30] and 
Del Chiaro et al [31]
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disease outcome is the tumour stage at the time of 
diagnosis[43]. Unfortunately pancreatic cancer often 
presents late and only 20% of patients with pancreatic 
cancer have surgically resectable disease at time of 
presentation[2,43]. In patients who are able to undergo 
successful surgical resection, 5-year survival is quoted 
as 27% whereas if the patient has locally advanced or 
metastatic disease the median survival is six to eleven 
months and two and six months respectively[44]. Despite 
advances in surgical and medical treatment of pancreatic 
cancer there has been a minimal improvement in the 
5-year survival rates. For example, population-based 
Northern Ireland cancer registry data revealed minimal 
improvements in five-year survival from 2.5% to 5.2% 
in cases diagnosed between 1993-1999 compared with 
2005-2009[45]. The rising incidence and ongoing poor 
survival figures highlight the need to identify methods 
of screening patients at high risk, develop methods of 
early detection and improve both surgical and medical 
management of these patients. 
PATHOLOGY OF PANCREATIC CANCER
Pancreatic adenocarcinoma and its variants account 
for 90% of all pancreatic carcinomas[46]. This section 
will briefly outline the pathology of pancreatic adeno-
carcinoma, its variants and precursor lesions. Non-
ductal tumours such as acinar cell carcinomas and 
neuroendocrine neoplasms will not be discussed here 
and for this, readers are directed elsewhere[47]. 
Approximately 60%-70% of pancreatic adenocar-
cinomas arise in the head of the pancreas with the 
remainder being found in the body (15%) and tail 
(15%). At the time of diagnosis most pancreatic adeno-
carcinomas have already spread beyond the pancreas 
and nodal metastases are not uncommon[48]. 
Morphological variants of pancreatic adenocarcinoma, 
recognised in the World Health Organisation classification 
of pancreatic tumours have different histological features 
compared to conventional pancreatic adenocarcinomas. 
These variants also differ in terms of prognosis and may 
have a different molecular signature[49-52]. The main 
variants of pancreatic adenocarcinomas are presented in 
Table 4.
PATHOGENESIS
Pancreatic adenocarcinoma develops following a series 
of step-wise mutations from normal mucosa (Figure 
2A) to specific precursor lesions and ultimately invasive 
malignancy[53]. The three best characterised precursors 
of this malignancy are pancreatic intraepithelial neoplasia 
(PanIN), intraductal papillary mucinous neoplasms 
(IPMN) and mucinous cystic neoplasms (MCN)[54]. Each 
of these has unique clinical, pathological and molecular 
characteristics. 
PanIN
Pancreatic intraepithelial neoplasia is a non-invasive 
microscopic lesion that occurs in the small (usually less 
than 0.5 cm) pancreatic ducts. It has been proposed that 
PanIN may have a role in the development of localised 
pancreatitis and that the resultant epithelial injury and 
repair cycles may further propagate the neoplastic 
process[55]. These lesions were first categorised in 2001 
and initially graded from 1-3, reflecting progressive 
neoplastic morphological changes[56]. More recently there 
has been a move to simplify the classification using a 
two-tiered system, with the suggestion that the historical 
grades of 1a/1b and 2 be classified as low grade PanIN 
(Figure 2B), and the original PanIN 3 revised to high 
grade (Figure 2C)[57]. 
A recent microsimulation model, using the original 
PanIN classification, has sought to shed further light 
on the natural history of these lesions. Based on this 
model, the authors estimate an overall chance of 1.5% 
for men and 1.3% for women progressing from PanIN 
1 to detectable pancreatic adenocarcinoma over their 
lifetime[58]. It was also estimated that it will take 11.3 
years for men and 12.3 years for women to transform 
from PanIN 3 to pancreatic adenocarcinoma[58]. This 
represents a possible window for screening prior to the 
development of invasive malignancy as will be discussed 
later.
IPMN
IPMNs are also well recognised as precursor lesions for 
pancreatic cancer[59]. They represent a broad group of 
pathology, being mainly classified as arising from the 
Diet, nutrition, physical activity and pancreatic cancer 
Decreases risk Increases risk 
Strong evidence Convincing Body fatness 
Probable Adult attained height
Limited evidence Limited - suggestive Red meat, Processed meat; alcoholic drinks (heavier 
drinking); foods and beverages containing fructose; foods 
containing saturated fatty acids 
Limited - no conclusion Physical activity; fruits; vegetables; folate; fish; eggs; tea; soft drinks; coffee; carbohydrates; 
sucrose; glycaemic index; glycaemic load; total fat; monounsaturated fat; polyunsaturated 
fats; dietary cholesterol; vitamin C; and multivitamin/mineral supplements
Strong evidence Substantial effect on risk unlikely 
Table 3  Summary of impact of dietary factors, nutrition and physical activity on pancreatic cancer risk
Adapted from World Cancer Research Fund Continuous Update Project[25].
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main pancreatic duct or one of the side branches. This 
distinction is important as the risk of malignancy is 
significantly different. For example, several studies found 
malignant cells, including carcinoma in situ, present in 
a mean of 70% of resected main duct IPMNs compared 
to a mean of 25% of side branch lesions that were 
removed[60]. 
Mucinous cyst neoplasms
Mucinous cyst neoplasms also represent premalignant 
lesions of the pancreas. They account for 25% of 
pancreatic cysts undergoing resection and are signifi-
cantly more common in women[53]. A retrospective study 
of 163 patients undergoing pancreatic resection for MCN, 
found malignancy in 17.5% of the lesions removed[61].
Given that 1% of abdominal computed tomography 
(CT) scans will identify a cystic lesion of the pancreas, 
it is imperative that clear guidelines exist to ensure 
the appropriate management of these potentially 
premalignant abnormalities[53]. European[62] and 
international[63] consensus papers have recently been 
published and are an important point of reference for 
clinicians dealing with these lesions. However, there is a 
lack of high-quality population-based studies investigating 
all premalignant lesions of the pancreas and future work 
is needed to progress our understanding of aetiology, 
trends in incidence and factors affecting progression to 
malignancy. This is particularly urgent given the known 
rise in pancreatic cancer incidence, and that a diagnosis 
of PanIN and/or pancreatic cysts represents a potential 
opportunity for intervention and patient management 
to minimise this risk of progression. On the other hand, 
this must be balanced with better understanding of 
which patients could be considered low-risk, which could 
provide reassurance both to the patient and minimise 
unnecessary burden on healthcare systems. 
Molecular understanding of pancreatic adenocarcinoma 
pathogenesis
PanIN is the most common precursor of pancreatic 
adenocarcinoma and this is supported by molecular 
studies that show that these lesions have genetic 
abnormalities that are common to adjacent pancreatic 
adenocarcinoma and the histological progression 
of PanIN parallels the accumulation of molecular 
abnormalities[46]. Lower grade PanIN lesions have 
mutations in the KRAS oncogene and exhibit telomere 
shortening, suggesting these are early changes on the 
pathway to invasive malignancy[64]. Mutations in p16, 
CDNK27, p53 and SMAD4 appear later and are present 
in higher grade PanIN and pancreatic adenocarcinoma. 
The rate of KRAS mutation also increases in relation to 
the grade of PanIN[53,65]. Abnormalities in notch signalling 
and sonic hedgehog pathways have also been implicated 
in pancreatic adenocarcinoma development and 80% of 
these mutations appear to be sporadic[9,43].
Recent genomic analysis identified 32 recurrently 
mutated genes in pancreatic adenocarcinoma and 
these were able to be stratified into four sub-groups 
namely squamous, pancreatic progenitor, immunogenic 
and aberrantly differentiated endocrine exocrine, 
each of which has a unique genomic signature which 
corresponded to histopathological findings and 
prognosis[66]. The squamous sub-type was associated 
with the adenosquamous histological variant of 
pancreatic adenocarcinoma and found to carry an 
independently poor prognosis. The pancreatic progenitor 
group highly expressed transcription factors involved in 
determining pancreatic cell lineage. Significant immune 
infiltration was found in the immunogenic tumours 
and the aberrantly differentiated endocrine exocrine 
tumours were associated with acinar cell carcinomas[66].
These findings shed further light on the complex and 
heterogenous nature of pancreatic cancer and may aid 
the development of more targeted, personalised therapy 
based on individual tumour biology.
Given that the majority of pancreatic tumours 
express androgen receptors (AR), the role of these in the 
pathogenesis of this disease has been an area of study 
for many years[67-69]. Some in vitro and mouse models 
have shown reduced cell line proliferation and tumour 
shrinkage with androgen receptor blockade[69]. However, 
Morphological Variant Characteristics
Adenosquamous carcinoma Significant components of ductal/glandular and squamous differentiation (at least 30%). Considered to have a 
worse prognosis than pancreatic adenocarcinoma.
Colloid/mucinous carcinoma Production of copious amounts of extracellular stromal mucin. Most arise in association with intraductal 
papillary mucinous neoplasms; thought to have more favourable prognosis than pancreatic adenocarcinoma
Undifferentiated/anaplastic carcinoma Minimal or no differentiation; highly atypical cells which may appear spindle shaped or sarcomatoid, often 
admixed with osteoclast-like giant cells. One of the most aggressive forms of pancreatic cancer with extremely 
poor survival rates
Signet ring cell carcinoma Discohesive, singly invasive cells with intracytoplasmic mucin that may displace the nucleus. Similar tumours 
throughout the gastrointestinal tract. Very rare form of pancreatic cancer with prognosis similar to that of 
pancreatic adenocarcinoma
Medullary carcinoma Syncytial arrangement of pleomorphic epithelial cells with associated intratumoral lymphoid infiltrate. 
Prognosis is slightly better than pancreatic adenocarcinoma
Hepatoid carcinoma Morphological similarity to hepatocellular carcinoma. May produce bile. Very rare tumour with a poor 
prognosis similar to that of pancreatic adenocarcinoma
Table 4  Summary of the different subtypes of pancreatic ductal adenocarcinoma[52]
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there is discordance between studies regarding AR 
expression in pancreatic adenocarcinoma and its possible 
role in pathogenesis[70]. A retrospective cohort study of 60 
patients who underwent pancreatic resection found that 
AR expression was not related to the grade of tumour 
or prognosis[70]. The relative lack of robust evidence 
prevents any current recommendation that therapies 
targeting AR be used in pancreatic adenocarcinoma and 
this is another area in need of further study[68,71].
DIAGNOSIS AND SCREENING
Pancreatic cancer poses a significant diagnostic challenge 
and the majority of cases present late, with either locally 
advanced or metastatic disease. The reasons for this 
are multi-factorial including the non-specific symptoms 
associated with the disease and the close proximity of 
major blood vessels which can be readily invaded by 
the tumour[72]. These factors mean that 80%-85% of 
tumours are not resectable at the time of presentation[43]. 
At present, surgical resection is the only potential cure for 
pancreatic cancer, although rates of recurrence are high 
with inevitably dismal rates of long-term survival.
Due to the low lifetime risk of pancreatic cancer 
(around 1%), population-based screening of unselected 
populations for this tumour is not recommended[31,73,74]. 
The International Cancer of the Pancreas Screening 
Consortium, recommends that individuals meeting the 
definition of familial pancreatic cancer (outlined in Table 
2) are a potential target for screening[73]. There was 
disagreement as to when to begin screening of these 
high risk populations, with just over half of the consensus 
group voting that screening should begin at 50[73]. If 
a non-suspicious cyst is found, surveillance should be 
repeated every 6-12 mo. Solid lesions, not meeting the 
criteria for immediate resection, and main pancreatic 
duct strictures should have repeat imaging after three 
months[73].
Whilst a high-risk population for screening has been 
identified, the best diagnostic imaging modalities and 
lesions which should be targeted are less well defined[73]. 
Secretin enhanced magnetic resonant imaging (MRI) 
and magnetic resonance cholangiopancreatography 
(MRCP) have been shown to have a good to excellent 
concordance with endoscopic ultrasound (EUS) findings 
when used as a one-time screening modality and 
avoids the risk of ionising radiation[73]. However, EUS 
has a higher sensitivity for identifying solid pancreatic 
lesions, less than 2cm, when compared to CT and 
MRI[75]. EUS is also able to identify worrisome features in 
pancreatic cysts and can be combined with fine needle 
aspiration cytology to help further characterise these 
lesions[73]. Historically it was felt that PanIN could not 
be reliably identified on imaging[76]. There is, however, 
emerging evidence that it may be associated with 
lobulocentric atrophy producing similar appearances 
to chronic pancreatitis on EUS[55,77]. In the high risk 
population outlined by the International Cancer of the 
Pancreas Screening Consortium group, consensus 
was that a combination of EUS and MRI/MRCP are the 
recommended imaging modalities for screening in these 
individuals[73].
Whilst the appropriate population and imaging 
modality for screening has been outlined, equipoise 
still exists as to the appropriate management of any 
identified abnormalities and further study is needed. 
A recent meta-analysis of screening programs in 
populations at high risk of pancreatic cancer found higher 
rates of curative resection and longer median survival 
when compared to controls[78]. These findings are 
promising, although must be balanced against the issue 
of heightened anxiety in the screened population[78].
Whilst general population-based screening is not 
recommended, various awareness campaigns have 
been established to highlight the often vague symptoms 
of pancreatic cancer and encourage individuals to seek 
medical attention early. One study highlighted that many 
people who were ultimately diagnosed with pancreatic 
cancer were falsely reassured by the intermittent nature 
of their symptoms over the preceding months[79]. The 
relative rarity of pancreatic cancer also means that many 
primary care physicians will only see a case every few 
years on average. It is therefore imperative to maintain 
awareness among these professionals in order that those 
with relevant symptoms are investigated in a timely 
and appropriate fashion. A retrospective case-control 
study in primary care found that patients sought medical 
attention 18 times on average in the period preceding 
Figure 2  Pathogenesis. A: Normal duct; B: Low grade pancreatic intraepithelial neoplasia (PanIN); C: High grade PanIN.
A B C
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their pancreatic cancer diagnosis[80].
BIOMARKERS FOR EARLY DETECTION
Investigation of potential biomarkers including liquid 
biopsy, to aid in screening, diagnosis, and treatment of 
pancreatic cancer has been an area of intense research. 
Efforts to detect biomarkers in blood, breath and 
pancreatic juice have all been investigated. 
Serum cancer antigen 19-9 (CA 19-9) is the only 
marker approved by the United States Food and Drug 
Administration for use in the routine management of 
pancreatic cancer[81]. The low positive predictive value 
of CA19-9 means it has no role in mass screening 
of asymptomatic patients and is only appropriate to 
monitor response to treatment and as a marker of 
recurrent disease[82]. Mass spectrometry of tumour 
tissue metabolites found increased levels of specific 
metabolic by-products in early stage pancreatic 
adenocarcinoma when compared to controls in a recent 
study. There was, however, discordance between the 
levels identified from tumour tissue and plasma samples 
suggesting further study is required if a blood based 
biomarker is to be developed[74]. More recent studies 
into plasma-based metabolite panels have shown more 
promise in relation to the early diagnosis of pancreatic 
adenocarcinoma in the general population[83] and in those 
with chronic pancreatitis and a higher risk of pancreatic 
adenocarcinoma[84]. The high rate of genetic mutation 
associated with pancreatic adenocarcinoma has also led 
to the investigation of cell free DNA and tumour cells in 
systemic circulation as a screening or diagnostic test. 
Riva et al[84] found that, despite the high rates of KRAS 
mutation in pancreatic tumour tissue, concentrations of 
circulating tumour cells or cell free DNA did not have the 
required level of sensitivity or specificity to enable their 
use as screening tests.
Other non-invasive alternatives to blood have been 
investigated as mediums for early detection biomarker 
research, namely the increased concentration of volatile 
organic compounds (VOC) in exhaled air specific. A 
recent case-control study found raised levels of VOC in 
patients with pancreatic cancer compared to healthy 
controls with a sensitivity and specificity of 100% and 
84% respectively[85]. This is another avenue of potential 
further study in the development of a non-invasive 
biomarker for pancreatic cancer.
The presence of DNA mutations in pancreatic 
juice has also been an area of study. Mutant P53 was 
found in the pancreatic juice of individuals with PanIN 
2-3, intermediate and high grade IPMN and invasive 
malignancy[86]. When next generation sequencing 
techniques were used, pancreatic cancer was more likely 
to have mutated DNA found in pancreatic juice than 
healthy controls[76]. A small number of patients who 
eventually developed invasive malignancy had evidence 
of mutated DNA in pancreatic juice samples pre-dating 
any abnormalities identified on imaging[76].
Whilst the discovery of biomarkers for the diagnosis 
of pancreatic adenocarcinoma continues, a recent review 
concluded that a lack of validated and specific biomarker 
for this disease remains a major challenge[87]. 
TREATMENT 
Surgical resection is the only treatment that offers a 
potential cure of pancreatic cancer and the addition of 
chemotherapy in the adjuvant setting has been shown to 
improve survival rates. There have been some optimistic 
results showing a further improvement in survival with 
the administration of chemo-radiotherapy in the neo-
adjuvant setting but further work is needed to identify 
which group of patients will benefit the most. The most 
up-to-date evidence supporting these treatment options 
is presented below. 
SURGICAL MANAGEMENT
Pancreatico-duodenectomy (Whipple’s procedure), 
distal or total pancreatectomy are the surgical options 
for the resection of pancreatic cancer depending on 
the anatomical location of the tumour or tumours. 
Reorganisation of healthcare services and restriction 
of these procedures to high volume centres has 
improved outcomes as surgeons’ expertise increases[20]. 
Innovations in technology and operative technique have 
sought to further reduce adverse outcomes and improve 
survival. The aim of surgical resection is to achieve an 
R0 resection as this is associated with a significantly 
improved survival compared to R1 resections[88]. Neo-
adjuvant treatment and vascular resections have 
been employed in an attempt to increase the rate of 
microscopic clearance. There is ongoing debate as to 
what constitutes an R1 resection with the Union for 
International Cancer Control and College of American 
Pathologists defining it as microscopic evidence of cancer 
cells at the definite resection margin whereas the Royal 
College of Pathologists define it as tumour within 1mm of 
the resection margin[89]. 
Pre-operative biliary drainage
A significant proportion of patients with pancreatic cancer 
present with jaundice. This can have implications with 
regards to coagulopathy and increased peri-operative 
infective complications[90]. Traditionally, patients with 
obstructive jaundice would have this relieved prior to 
resection taking place.
A Cochrane review comparing the outcomes of five 
studies investigating pre-operative biliary drainage (4 
via percutaneous transhepatic cholangiography and 1 
using endoscopic retrograde cholangiopancreatography 
(ERCP) found no evidence for or against drainage, 
although the evidence was acknowledged to be poor[91]. 
However, a recent multi-centre randomised trial of ERCP 
and drainage vs immediate surgery found a higher 
rate of peri-operative complications in the drainage 
group[92]. This suggests that a select group of patients 
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may do better with expedited surgery rather than biliary 
decompression, followed by resection.
Anastomotic technique
A major source of morbidity following Whipple’s pro-
cedure is leak from the pancreatic anastomosis and 
formation of a pancreatic fistula[93]. It is possible to 
reconstruct the alimentary tract following Whipple’s by 
anastomosing the pancreatic remnant to the stomach or 
jejunum. A recent Cochrane review found no difference in 
outcome when these two techniques were compared to 
each other[94]. Variations in anastomotic technique have 
also been described but a recent meta-analysis failed 
to demonstrate reduced rates of pancreatic fistula with 
the “duct-to-mucosa” anastomosis vs the “invagination” 
technique[94].
Minimally invasive surgery
In line with other areas, interest has grown in minimally 
invasive techniques for pancreatic surgery. Laparoscopic 
distal pancreatectomy was the first minimally invasive 
pancreatic resection to be described. One meta-analysis 
found comparable morbidity and mortality between 
laparoscopic and open distal pancreatectomy, with 
reduced blood loss and length of stay in the minimally 
invasive group. There was no difference in the rate of 
positive resection margins[95]. A further meta-analysis 
stated that laparoscopic distal pancreatectomy was at 
least non-inferior to the open procedure, but lack of 
level one evidence meant that it could not be deemed 
superior[96]. 
Attempts have also been made to use robotic 
techniques to improve Whipple’s procedure. When 
compared to open pancreatectomy, a meta-analysis of 
retrospective cohort studies found a lower complication 
rate and less margin involvement in the robotic group[97]. 
However, the lack of randomisation in these studies 
leaves them open to selection bias. Robotic surgery also 
requires a significant capital investment and no cost-
effectiveness evaluations were included in any of the 
papers[98]. 
Vascular resection
The relationship between any pancreatic tumour and the 
surrounding vasculature is an important determinant 
of resectability[99]. Whilst it is often technically feasible, 
the benefit of resection of mesenteric and portal vessels 
invaded by tumour remains a controversial topic[99].
Meta-analysis of studies involving patients undergoing 
Whipple’s procedure with or without major arterial 
resection found higher rates of peri-operative mortality 
and poor outcomes at year one and three in the group 
undergoing arterial reconstruction[100]. For this reason, 
invasion of the superior mesenteric artery or coeliac trunk 
remains a largely accepted contraindication to resection. 
Outcomes from venous resection, however, may be 
more promising. A meta-analysis of 22 retrospective 
cohort studies found no difference in perioperative 
morbidity, one or three-year survival in those undergoing 
resection of the portal or superior mesenteric vein when 
compared to those in whom no vascular intervention 
was undertaken. Unsurprisingly, there was an increased 
operative time and blood loss recorded in the venous 
resection group[101]. As stated previously, the lack of 
randomisation leaves these studies at risk of selection 
bias. However, combined pancreatectomy and venous 
resection may have a role in a select group of patients.
MEDICAL MANAGEMENT
Adjuvant treatment
The use of adjuvant chemotherapy was supported by 
the landmark randomised CONKO-001 study which 
compared adjuvant gemcitabine after complete surgical 
resection against surgery alone. This study demonstrated 
a significantly improved median disease free survival 
(13.4 mo vs 6.7 mo) and overall survival with a five year 
survival of 20.7% vs 10.4% and ten year survival of 
12.2% vs 7.7%[102]. However, despite these promising 
results the median overall survival only improved from 
20 to 23 mo (P = 0.01)[102]
Further studies have sought to identify the best 
chemotherapy regime. The ESPAC-3 trial demonstrated 
that gemcitabine was the chemotherapy agent of 
choice when compared to 5-fluorouracil[103]. Although 
survival outcomes were comparable in both groups, the 
latter was less well tolerated[103]. Due to the success of 
dual therapy of capecitabine and gemcitabine in both 
advanced and metastatic disease, Neoptolemos et al[103] 
performed the ESPAC-4 trial in patients with resected 
disease and found that the median overall survival was 
28 mo (95%CI: 23.5-31.5) in dual therapy compared 
to 25.5 mo (22.7-27.9) in gemcitabine alone (HR: 0.82, 
95%CI: 0.68-0.98; P = 0.032). 
Other chemotherapy regime have been studied, for 
example, in the PRODIGE24/CCTG randomised clinical 
trial which compared the outcomes of gemcitabine or 
mFOLFIRONOX (a combination of oxaliplatin, irinotecan, 
and leucovorin) in patients with an R1 or R0 resection 
of pancreatic adenocarcinoma[104]. The results at a 
median follow up time of 33.6 mo have shown that 
administration of mFOLFIRONOX was associated with 
a significantly improved disease-free survival (21.6 
mo vs 12.8 mo), and overall survival (54.4 mo vs 35 
mo) compared to gemcitabine[105]. Administration of 
mFOLFIRONOX was associated with a significantly 
increased risk of complications although the only death 
that occurred was within the gemcitabine treatment 
group[105]. The current standard of care is guided by post-
operative fitness and mFOLFIRONOX is used for very fit 
patients with tumours of the head, body and tail of the 
pancreas whereas in less fit patients dual therapy with 
gemcitabine and capecitabine is given[105]. Single agents 
(usually 5-Fu) are used for periampullary tumours as 
there is insufficient evidence for the same treatment as 
the previously mentioned tumours[106].
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Neo-adjuvant treatment
Although there has been shown to be a survival benefit 
with adjuvant treatment, between 71% and 76% 
per cent of patients still relapse within two years up. 
Furthermore, due to complications associated with 
surgery up to 40% of patients are not suitable for 
progression to adjuvant therapy[105]. Such figures coupled 
with the success seen with neo-adjuvant treatment in 
several other cancers including rectal, oesophageal, and 
gastric cancer have led to the exploration of the impact 
of neo-adjuvant treatment in pancreatic cancer[107].
The theoretical advantage of neo-adjuvant therapy 
includes eliminating micro-metastases and shrinkage 
of the primary tumour and both these factors are 
associated with a decreased incidence of tumour 
recurrence[108]. However, patients receiving neo-adjuvant 
treatment may develop complications which can delay 
or prevent the progression to surgery and tumours may 
be unresponsive to the chemoradiotherapy leading to 
disease progression and previously resectable disease 
becoming unresectable. Furthermore, the administration 
of chemo radiotherapy induces fibrosis within the 
pancreas which can increase the complication rate 
associated with pancreatectomy[109]. 
Studies looking at the impact of neo-adjuvant 
treatment have been performed in patients with re-
sectable or borderline resectable disease. The definition 
of resectable disease is in those patients who have no 
involvement of the superior mesenteric artery, coeliac 
axis, portal vein or superior mesenteric vein whereas the 
definition of borderline resectable disease is based on the 
degree of involvement of these major venous and arterial 
structures[110]. 
Multiple meta-analyses have been performed 
studying the impact of neoadjuvant treatment on 
survival in pancreatic adenocarcinoma. The most recent 
was by Versteijne et al[110] which included 38 studies 
with a combination of 3 randomised controlled trials, 9 
phase one or phase two trials, 12 prospective cohort 
studies and 14 retrospective cohort studies. In intention-
to-treat analysis there was a median overall survival of 
18.8 mo in the neo-adjuvant group compared to 14.8 
mo in the surgery first group. For those who actually 
underwent surgery the median survival time was 15 
mo in the surgery-first group, compared to 26.1 mo in 
the neoadjuvant treated group. The overall resection 
rate was lower in the neoadjuvant group compared to 
those who had surgery first (66% vs 81.3%; P < 0.001) 
however the R0 resection rate was higher in patients who 
had neo-adjuvant treatment compared to those who had 
surgery first (86.8% vs 66.9%; P < 0.001)[111]. 
The ongoing Preopanc-1 trial is a Dutch study which 
recruited 246 patients with resectable or borderline 
resectable disease[112]. Patients were randomised to 
either immediate surgery or to pre-operative che-
moradiotherapy followed by surgery. There was an 
increased rate of resection in the immediate surgery 
group (72%) compared to the group which received 
preoperative chemoradiotherapy (60%) although this 
did not reach a level of statistical significance. There 
was an improved survival in intention to treat analysis 
with 17.1 mo in the neoadjuvant group compared to 
13.7 mo in the immediate surgery group although this 
did not reach statistical significance (P = 0.07) either. 
In patients who underwent an R0 or R1 resection there 
was a significantly improved overall survival in the neo-
adjuvant group (42.2 mo vs 16.8 mo; P < 0.001) and 
there was also a significantly increased time until distant 
metastases (P = 0.01) and loco regional recurrence (P = 
0.002)[112]. It should be noted that the evidence base for 
neo-adjuvant treatment in pancreatic cancer is based on 
phase two trials and meta-analysis while the results of 
phase three trials are awaited. 
TREATMENT IN METASTATIC PATIENTS
The management of metastatic pancreatic cancer 
involves symptom control, management of jaundice and 
palliative chemotherapy with the preferred chemotherapy 
regime FOLFIRONOX (mFOLFIRINOX with 5-fluorouracil). 
Conroy et al[112] performed a multicentre, randomised 
trial in 48 French centres with patients receiving either 
gemcitabine or FOLFIRINOX within a week of enrolment. 
There were 171 patients within each group and intention 
to treat analysis was performed. The median overall 
survival in the FOLFIRONOX group was 11.1 mo (95%CI: 
9.0-13.2) compared to 6.8 mo (95%CI: 5.5-7.6) in the 
gemcitabine group (HR: 0.57 95%CI: 0.45-0.73; P < 
0.001). There was an increased incidence of adverse 
affects within the group receiving FOLFIRONOX however, 
this group concluded that FOLFIRONOX should be 
the treatment of choice in patients with metastatic 
disease[114]. 
FUTURE DIRECTIONS FOR PANCREATIC 
CANCER TREATMENT
The limitations of current treatment strategies in pan-
creatic cancer reinforces the need for new avenues of 
research to be explored, in order to achieve potential 
breakthroughs. Novel therapeutic modalities including 
oncolytic viral therapy and gene editing technology 
have been identified as promising in several pre-clinical 
and early phase clinical trials[114,115]. These therapeutic 
strategies have been recently reviewed by Rouanet 
et al[116], which provides an excellent overview of the 
current landscape of these experimental treatments. 
SUMMARY AND FUTURE RESEARCH 
RECOMMENDATIONS
Pancreatic cancer is more common in developed coun-
tries, which may be attributed to lifestyle factors. 
Aetiology is still poorly understood, and further large, 
prospective studies are necessary to better understand 
risk factors associated with pancreatic cancer.
Patients with a risk of familial pancreatic ductal 
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adenocarcinoma are a potential target for screening. 
However, the optimum age, time interval at which 
screening should be performed or the best imaging 
technique is not agreed upon. Further retrospective and 
prospective studies which follow these patients with 
familial pancreatic cancer over time will help gain a better 
understanding of the course of this disease and enable 
the introduction of effective screening and treatment 
methods.
PanIN, IPMN and MCN are recognised precursors to 
pancreatic adenocarcinoma. Identifying patients with 
these lesions early, and developing an appropriate follow 
up programme will enable early treatment in high risk 
patients but also prevent unnecessary surgery in low 
risk lesions. This can be achieved by performing large 
retrospective and prospective studies which follow 
these patient groups over prolonged periods of time 
which will enable a better understanding of the disease 
process to be achieved. Furthermore, the risk factors 
associated with these pre-malignant conditions will be 
able to be identified, which opens the possibility of target 
populations being screened for these pre-malignant 
conditions. 
The introduction of neo-adjuvant therapy has improved 
survival in some patients whereas others with previously 
resectable disease have developed unreseactable disease 
during the course of their treatment. Further randomised 
studies are essential to identify which patients will 
benefit most from this approach. The discovery of novel 
biomarkers may contribute to the decision-making process 
and enable precision medicine and therapy tailored to 
individual patients. 
Surgical resection remains the mainstay of curative 
treatment of pancreatic cancer. Venous resection enables 
clear margins to be achieved but the survival benefit 
from this is not clear. Further retrospective studies 
identifying patients who have undergone this treatment 
and the outcomes associated with it will add to the 
evidence pool and help formulate future guidelines.
CONCLUSION
This review provides a comprehensive account of the 
epidemiology and management of pancreatic ductal 
adenocarcinoma. Significant gaps (as highlighted in the 
summary section above) remain in the understanding of 
this disease and treatment options although continually 
evolving continue to have limited success. There has 
been a recent drive to fund large consortia and specialist 
research into pancreatic ductal adenocarcinoma but there 
is much work to be done to enable similar breakthroughs 
as seen for other cancer sites.
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